Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Phase II, Prospective, Single-arm, Multicenter Trial
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Jun 2021 Results evaluating efifcacy and adverse effects of the oral vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitorapatinib in patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESCC) published in the Oncologist
- 24 Jan 2021 Status changed from active, no longer recruiting to completed.
- 03 Feb 2019 Status changed from recruiting to active, no longer recruiting.